Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Kjønnsforskjeller i responsen på avholdenhet fra alkohol. (SPAR)

2. november 2026 oppdatert av: Martin Plawecki, Indiana University

In laboratory animals, repeated cycles of abstinence from and return to alcohol drinking can lead to changes in alcohol intake. In a study of the effect of abstinence on drinking in humans, the investigators found evidence that abstinence affects drinking differently in women compared to men. In the present study, the investigators propose to study how men and women respond to abstinence, and whether this information can be used to improve intervention and prevention strategies.

Studieoversikt

Detaljert beskrivelse

Women and men differ in how quickly they progress from social to problematic alcohol drinking. In laboratory animals, short-term abstinence increases alcohol consumption, with repeated deprivations leading to disordered drinking. In a preliminary study, the investigators found that men and women differed in how their motivation to drink alcohol changed after a short period of abstinence. The investigators hypothesize that this difference may affect their transition to alcohol use disorders. The objectives of this application are to characterize the human post abstinence response, and use identical alcohol exposures to study the mechanisms underlying identified sex differences. In addition, the investigators will complete a 2 year prospective study of natural drinking patterns to assess how self-reported abstinence intervals influence drinking trajectories. The long-term goal of this project is to inform alcohol use disorder treatment and to design and test novel interventions using the laboratory model of post-abstinence response. There is a critical unfilled need to understand sex differences in disease progression, and this lab-based assessment coupled to longitudinal follow-up provides the rigorous experimental design to begin to meet that need. This project will increase scientific knowledge by advancing the translation between preclinical and clinical models, eventually informing sex-specific intervention and prevention strategies for problematic drinking and establishing a model to test those interventions..

Studietype

Intervensjonell

Registrering (Antatt)

160

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Rekruttering
        • University Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Martin H Plawecki, MD, PhD
        • Hovedetterforsker:
          • Melissa A Cyders, PhD
        • Underetterforsker:
          • Wei Wu, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

21 år til 35 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Moderate social drinkers
  • Able to understand/complete questionnaires and procedures in English
  • Body mass index (BMI) between 18.5 and 32 kg/m2
  • Have venous access sufficient to allow blood sampling

Exclusion Criteria:

  • Pregnant or breast-feeding women, or women who intend to become pregnant
  • Do not attest to using accepted forms of birth control for the infusion phase of the study
  • Current treatment for, or desire to be treated for, any substance use disorder or court ordered to not drink alcohol
  • History of significant adverse reaction to alcohol
  • Medical disorders or other conditions such as alcohol withdrawal seizures or delirium tremens that may influence study outcome or participant safety
  • Medications (past 30 days) that could influence data or participant safety (e.g. antidepressants, antipsychotics, benzodiazepines, etc.) as determined by investigators
  • DSM 5 Disorders (non AUD) or current/history of neurological disease of cerebral origin, or head injury with > 20 min loss of consciousness
  • Positive breath alcohol reading on arrival at any study visit
  • Actively suicidal (for example, any suicide attempts within the past year or any current suicidal intent, including a plan) or are at serious suicidal risk, by clinical judgment of the investigator
  • Any condition for which the principal investigators determine it is unsafe or not prudent to enroll

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Free access alcohol self-administration

During the 2.5-hour free-access self-administration sessions, the participant may choose to complete a task for an alcohol or water reward. Interventions include Abstinence from Alcohol and Usual Drinking

Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol

Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior

During the laboratory alcohol infusion sessions, alcohol is infused through an indwelling catheter.

Andre navn:
  • 6,0& (v/V) etanolløsning
Eksperimentell: Clamped alcohol exposure

A battery of behavioral tasks will be administered to participants before, and at the beginning and end of a 3 hour clamped exposure to alcohol (fixed at 80 mg/dL). EEG will be recorded throughout to assess event related potentials associated with task performance. Interventions include Abstinence from Alcohol and Usual Drinking.

Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol

Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior

During the laboratory alcohol infusion sessions, alcohol is infused through an indwelling catheter.

Andre navn:
  • 6,0& (v/V) etanolløsning

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Sex differences in the effect of abstinence on alcohol self-administration.
Tidsramme: 2 single day laboratory sessions, one following 2 weeks alcohol abstinence

The effect of 2 weeks abstinence on intravenous alcohol intake will be compared in men and women.

2 single day laboratory sessions, one following 2 weeks alcohol abstinence
Sex differences in the effect of abstinence on sensitivity of the P3 response to alcohol.
Tidsramme: 2 single day laboratory sessions, one following 2 weeks alcohol abstinence

The effect of 2 weeks abstinence from alcohol on sensitivity of the neurophysiological P3 response to alcohol, assessed using a stop-signal response task, will be compared in women and men during an iv infusion clamp.

2 single day laboratory sessions, one following 2 weeks alcohol abstinence
Sex differences in the effect of abstinence on subjective responses to alcohol.
Tidsramme: 2 single day laboratory sessions, one following 2 weeks alcohol abstinence

The effect of 2 weeks abstinence from alcohol on subjective responses to alcohol in women and men will be assessed using a survey during an iv infusion clamp.

2 single day laboratory sessions, one following 2 weeks alcohol abstinence
The role of changes in alcohol elimination on sex differences in response to abstinence.
Tidsramme: 2 single day laboratory sessions, one following 2 weeks alcohol abstinence

The effect of 2 weeks abstinence from alcohol on alcohol elimination in men and women will be assessed using an iv alcohol infusion clamp.

2 single day laboratory sessions, one following 2 weeks alcohol abstinence

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Response to abstinence as a predictor of alcohol risk in women and men.
Tidsramme: 2 years

For both Arm 1 and Arm 2, daily alcohol consumption will be surveyed every 2 months for 2 years following the laboratory sessions. Self-imposed periods of abstinence will be assessed to determine if subsequent daily alcohol intake increases or decreases, and to determine if men and women differ in the effect of abstinence on drinking.

2 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Martin H Plawecki, MD, PhD, Psychiatry, Indiana University School of Medicine
  • Hovedetterforsker: Melissa A Cyders, PhD, Psychology, Indiana University-Purdue University at Indianapolis

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. april 2019

Primær fullføring (Antatt)

28. februar 2027

Studiet fullført (Antatt)

28. februar 2029

Datoer for studieregistrering

Først innsendt

12. november 2018

Først innsendt som oppfylte QC-kriteriene

30. januar 2019

Først lagt ut (Faktiske)

1. februar 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

The final raw dataset will be available to other researchers when we have collected all subjects and completed our own planned analyses. Prior to completion of our own planned analyses, we would be willing to consider releasing the dataset upon request. We will work with our IRB to establish a strategy for de-identifying the data while retaining the ability to ensure the quality of the stored data, and develop a data-sharing agreement.

IPD-delingstidsramme

After all subjects have been collected and the primary outcomes accepted for publication. The dataset will be available indefinitely,

Tilgangskriterier for IPD-deling

On request to the PIs

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere